Bausch & Lomb Corp

Listed Company

BLCOCIK 0001860742NYSELarge AcceleratedOphthalmic GoodsCAFY ends Dec 31

Period

FY 2025

Revenue

$5.10B

Net Income

$-360.00M

Total Assets

$14.02B

Equity

$6.45B

Shares Out

356.54M

Op. Cash Flow

$283.00M

Business

Bausch & Lomb Corp is a fully integrated eye health company that develops, manufactures and commercializes products and technologies to protect and enhance vision across the continuum of care. It offers a comprehensive portfolio including contact lenses and daily disposables, lens care solutions, OTC eye drops, nutritional supplements, prescription ophthalmic pharmaceuticals, intraocular lenses and surgical systems, instruments and consumables. The company reports results through three operating segments: Vision Care, Pharmaceuticals and Surgical. It distributes products globally in approximately 100 countries through direct sales forces, independent distributors, wholesalers, retailers and eye care professionals.

Summary from filing dated 2025-02-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	5,101	4,791	4,146	3,768	3,765
Selling, general and administrative (Note 3)	2,234	2,082	1,736	1,478	1,389
Research and development	371	343	324	307	271
Amortization of intangible assets	258	288	240	244	292
Other expense, net	75	44	74	13	17
Total expenses	4,988	4,629	4,016	3,561	3,436
Operating income	113	162	130	207	329
Interest income	12	15	15	6	0
Interest expense	−421	−399	−283	−146	0
Loss on extinguishment of debt	−6	0	0	—	—
Foreign exchange and other	−15	−12	−28	6	−11
Loss before provision for income taxes	−317	−234	−166	73	318
Provision for income taxes	−35	−71	−82	−58	−125
Net loss	−352	−305	−248	15	193
Net income attributable to noncontrolling interest	−8	−12	−12	−9	−11
Net loss attributable to Bausch + Lomb Corporation	−360	−317	−260	6	182
Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share)	−1.02	−0.9	−0.74	0.02	0.52
Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share)	−1.02	−0.9	−0.74	0.02	0.52
Basic weighted-average common shares (in shares)	354	352	351	350	350
Diluted weighted-average common shares (in shares)	354	352	351	350	350

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	383	305	331	354	174
Restricted cash	14	11	3	26	3
Trade receivables, net	1,221	1,026	839	724	721
Inventories, net	976	1,036	1,028	628	572
Prepaid expenses and other current assets (Note 3)	383	410	541	405	165
Total current assets	2,977	2,788	2,742	2,137	1,635
Property, plant and equipment, net	1,762	1,485	1,390	1,300	1,225
Intangible assets, net	3,281	3,494	3,589	2,058	2,264
Goodwill	4,758	4,523	4,575	4,507	4,586
Deferred tax assets, net	934	885	921	927	933
Other non-current assets (Note 3)	310	294	225	215	180
Total assets	14,022	13,469	13,442	11,144	10,823
Accounts payable (Note 3)	388	389	522	370	239
Accrued and other current liabilities	1,493	1,309	1,027	901	860
Current portion of long-term debt and other financial liabilities	39	40	—	—	—
Total current liabilities	1,920	1,738	1,579	1,296	1,099
Deferred tax liabilities, net	19	13	14	7	24
Other non-current liabilities	521	430	397	329	298
Long-term debt and other financial liabilities	5,043	4,744	—	—	—
Total liabilities	7,503	6,925	6,522	4,043	1,421
Commitments and contingencies (Notes 19 and 20)	—	—	—	—	—
Common shares, no par value, unlimited shares authorized, 354,209,319 and 352,402,374 issued and outstanding at December 31, 2025 and December 31, 2024, respectively	0	0	0	0	0
Additional paid-in capital	8,563	8,429	8,349	8,285	0
Accumulated deficit	−931	−571	−254	6	0
Accumulated other comprehensive loss	−1,184	−1,385	−1,245	−1,258	−1,035
Total Bausch + Lomb Corporation shareholders equity	6,448	6,473	6,850	7,033	9,329
Noncontrolling interest	71	71	70	68	73
Total equity	6,519	6,544	6,920	7,101	9,402
Total liabilities and equity	14,022	13,469	13,442	11,144	10,823

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization of intangible assets	421	436	382	379	415
Amortization and write-off of debt premiums, discounts and issuance costs	18	20	30	8	0
Asset impairments	0	5	0	1	12
Acquisition-related contingent consideration	−27	−9	2	—	—
Allowances for losses on trade receivables and inventories	31	26	21	25	37
Deferred income taxes	−32	−10	−10	−90	116
Gain on sale of assets	−6	−5	0	0	—
Share-based compensation	149	92	74	62	62
Foreign exchange gain	2	10	12	−7	12
Gain excluded from hedge effectiveness	−10	−13	−13	−6	0
Amortization of inventory step-up resulting from acquisitions	62	82	23	—	—
Other	3	−10	−3	−23	−1
Trade receivables	−148	−227	−121	−95	−107
Inventories	38	−147	−264	−106	−15
Prepaid expenses and other current assets	20	161	−147	−7	−13
Accounts payable, accrued and other liabilities	108	126	245	189	163
Net cash provided by (used in) operating activities	283	232	−17	345	873
Acquisitions and other investments	−122	−138	−1,941	−45	−16
Purchases of property, plant and equipment	−349	−291	−181	−175	−193
Purchases of marketable securities	−11	−12	−17	−17	−19
Proceeds from sale of marketable securities	8	14	16	22	14
Proceeds from sale of assets and businesses, net of costs to sell	7	2	1	0	0
Interest settlements from cross-currency swaps	12	13	13	0	0
Net cash used in investing activities	−455	−412	−2,109	−215	−214
Issuance of long-term debt, net of discounts, and other financial liabilities	3,357	631	2,276	2,440	0
Repayments of debt	−3,096	−430	−161	−13	0
Payment of employee withholding taxes related to share-based awards	−15	−12	−10	0	0
Payments of financing costs	−12	0	−16	−3	0
Payments of noncontrolling interest distributions	−9	−10	−9	−11	−10
Other	0	−1	−2	0	0
Net cash provided by financing activities	225	178	2,078	81	−712
Effect of exchange rate changes on cash and cash equivalents and restricted cash	28	−16	2	−8	−8
Net increase (decrease) in cash and cash equivalents and restricted cash	81	−18	−46	203	−61
Accrued purchases of property, plant and equipment	51	56	65	38	31

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro